Clinical stage biopharmaceutical company DiaMedica has completed enrollment of type 2 diabetic patients in the DM199 single ascending dose (SAD) clinical study.
The randomized study is designed to assess three dose levels each in type 2 diabetic patients. DiaMedica chairman and CEO Rick Pauls said, “Completion of the enrollment of Type 2 Diabetic patients into the SAD portion of the Phase I/II clinical study is an important milestone in our DM199 development pathway.”
The primary objective of the SAD portion of the ongoing study is acute safety, tolerability and pharmacokinetic properties for the first time in type 2 diabetic patients, in addition to the efficacy of DM199 on improving glucose control.
The top line results from the placebo-controlled, double-blinded study are expected to be available in the third quarter of 2013.